The Journal of Immunology · 2010 · 10 citations · 45 references
MedicineImmunologyOncologyCancer ImmunologyImmunizationTumor ImmunologyCancer ImmunotherapyCancer VaccinesDendritic Cell BiologyImmune Response To VaccinationTherapeutic VaccinationVaccinationCancer Vaccine ImmunologyCancer Vaccine ResponsesPeptide VaccinationTherapeutic Cancer ImmunizationTumor Antigen ImmunogenicityTumor Antigen VaccinesTumor ImmunogenicityTumor Lysate Vaccines
Efficient tumor vaccination frequently requires adjuvant. Concomitant induction of an autoimmune response is discussed as a means to strengthen a weak tumor Ag-specific response. We asked whether the efficacy of dendritic cell (DC) vaccination with the renal cell carcinoma Ags MAGE-A9 (MAGE9) and G250 could be strengthened by covaccination with the renal cell carcinoma autoantigen GOLGA4. BALB/c mice were vaccinated with DC loaded with MHC class I-binding peptides of MAGE9 or G250 or tumor lysate, which sufficed for rejection of low-dose RENCA-MAGE9 and RENCA-G250 tumor grafts, but only retarded tumor growth at 200 times the tumor dose at which 100% of animals will develop a tumor. Instead, 75-100% of mice prevaccinated concomitantly with Salmonella typhimurium transformed with GOLGA4 cDNA in a eukaryotic expression vector rejected 200 times the tumor dose at which 100% of animals will develop tumor. In a therapeutic setting, the survival rate increased from 20-40% by covaccination with S. typhimurium-GOLGA4. Autoantigen covaccination significantly strengthened tumor Ag-specific CD4(+) and CD8(+) T cell expansion, particularly in peptide-loaded DC-vaccinated mice. Covaccination was accompanied by an increase in inflammatory cytokines, boosted IL-12 and IFN-gamma expression, and promoted a high tumor Ag-specific CTL response. Concomitant autoantigen vaccination also supported CCR6, CXCR3, and CXCR4 upregulation and T cell recruitment into the tumor. It did not affect regulatory T cells, but slightly increased myeloid-derived suppressor cells. Thus, tumor cell eradication was efficiently strengthened by concomitant induction of an immune response against a tumor Ag and an autoantigen expressed by the tumor cell. Activation of autoantigen-specific Th cells strongly supports tumor-specific Th cells and thereby CTL activation.
45
Marie‐Caroline Dieu‐Nosjean, Catherine Massacrier, Bernhard Homey et al. · The Journal of Experimental Medicine · 2000 · 373 citations · Full text
Martijn S. Bijker, Susan J. F. van den Eeden, Kees L. M. C. Franken et al. · European Journal of Immunology · 2008 · 231 citations · Full text
Life Sciences, Immunology, Oncology +17
Kayo Inaba, William J. Swiggard, Ralph M. Steinman et al. · Current Protocols in Immunology · 2009 · 211 citations